View ValuationTristel 향후 성장Future 기준 점검 2/6Tristel (는) 각각 연간 14.6% 및 10% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 27.3% 로 예상됩니다.핵심 정보14.6%이익 성장률14.21%EPS 성장률Medical Equipment 이익 성장16.2%매출 성장률10.0%향후 자기자본이익률27.33%애널리스트 커버리지Good마지막 업데이트16 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 03Tristel plc Recommends Interim Dividend for the Year Ended 30 June 2026, Payable on 9 April 2026The Board of Tristel plc recommended an interim dividend of 5.68 pence (2024: 5.68 pence) for the year ended 30 June 2026 to be paid on 9 April 2026. The associated ex-dividend date will be 19 March 2026 with a record date of 20 March 2026.공시 • Feb 06Tristel plc to Report First Half, 2026 Results on Mar 02, 2026Tristel plc announced that they will report first half, 2026 results on Mar 02, 2026공시 • Jan 22Tristel plc Announces Resignation of Matt Sassone as Chief Executive OfficerTristel plc announced that Matt Sassone, Chief Executive Officer, has confirmed to the Board his decision to resign to take up a worldwide President role with a large US multinational, leading a significant global business. Matt will actively continue in post until the end of the financial year and has fully committed to continue leading the business through this period. The Board has already commenced the process to appoint a new CEO and is confident that there is sufficient management depth in the business to ensure that trading will not be impacted during the transition.공시 • Nov 24Tristel plc Updates US Guidelines for High Level DisinfectionTristel plc expanded guidelines on the handling and reprocessing of ultrasound probes in healthcare environments. For the first time, the AIUM guidelines include chlorine dioxide as an accepted option for high-level disinfection ("HLD"). Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is manufactured and distributed by Parker Laboratories under an exclusive partnership agreement with Tristel, and is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes available in the US market.공시 • Nov 18Tristel plc, Annual General Meeting, Dec 11, 2025Tristel plc, Annual General Meeting, Dec 11, 2025. Location: the companys registered office, unit 1b lynx business park, fordham road snailwell, newmarket, cambridgeshire, cb8 7ny, United Kingdom공시 • Sep 27Tristel plc Announces the Launch of Its New Ultrasound Probe Decontamination ProductTristel plc announced the launch of its new ultrasound probe decontamination product, Tristel VISICLEAN™?, the first detergent of its kind with colour technology, enabling visible coverage and confirmation of high level disinfection. Tristel VISICLEANtm is deployed on the ultrasound probe, dying it pink, and when exposed to Tristel ClO2 via Tristel DUO ULT™?, the pink dye disappears, visibly verifying that the probe has been high level disinfected. Tristel VISICLE AN™? is now available within the VISI Combination Pack, a convenient, all-in-one solution for ultrasound probe decontamination. Effective high-level disinfection begins with cleaning, which eliminates organic matter and reduces microbes to ensure proper sterilisation. This is performed manually and must be done each time. Tristel VISICLEan™? is the only cleaning solution with visible verification, ensuring full auditability and compliance with protocols. Tristel VISICLEAC™?, DUO ULT™? and DRY WIPEStm, the products within the VISI Combination pack includes the Company's new product, Tristel VISVEAN™?, along with two pre-existing products, Tristel DUO U LT™? & Tristel DRY WIPESt m. Together, these products enable clinicians to perform manual decontamination procedures with confidence, precision, and audit-ready traceability via Tristel's 3T™? digital platform. VISI Combination Packs are now available to healthcare providers across the UK and are being launched globally on a phased basis, as and when the Company secures the necessary local regulatory clearances. Tristel's proprietary chlorine dioxide chemistry is globally trusted for its broad-spectrum efficacy and resistance-proof mechanism. With over 30 years of experience in high-level disinfection, Tristel continues to remain at the forefront of infection prevention.공시 • Sep 16Tristel plc to Report Fiscal Year 2025 Results on Oct 13, 2025Tristel plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Oct 13, 2025공시 • May 12Tristel plc Announces FDA Clearance for Tristel OPH Ophthalmic High-Level Disinfectant Now Approved for Immediate Sale in the USTristel plc announced that the U S Food and Drug Administration ("FDA") has completed its review of the Company's 510(k) filing for Tristel OPH, and has granted its clearance for immediate sale. Tristel OPH is a high-level disinfectant ("HLD") foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters, lenses, retinal imaging probes, A-scan and B-scan biometry probes that make contact with the cornea. With c.16 million ophthalmic procedures taking place every year in North America, the Board believes that FDA clearance has the potential to transform ophthalmic disinfection practice in the region. Until now, the only FDA-cleared HLD method available for ophthalmic devices involves soaking in an open tray. This method is slow, given the long contact times required to be effective, and has as a result proven to be impractical to implement at point of care. In addition, the use of chemicals, such as sodium hypochlorite or hydrogen peroxide in an open tray, leads to occupational health concerns and may require costly implementation of ventilation. Prolonged exposure in a chemical soak can also lead to device damage. To address the problems, some clinics have turned to costly single-use devices, for which there is not always an option, while others have compromised by using low-level disinfectants options, such as alcohol wipes. In comparison, Tristel OPH has a short contact time of two minutes, is compatible with all widely used ophthalmic medical devices, is easily used at the point of care and is instantly deployable. The Company has already established local US manufacturing with its partner Parker Laboratories, and numerous leading eye institutes in the US have already approached Tristel to become early adopters in anticipation of FDA clearance for Tristel OPH. Tristel OPH directly addresses a long-standing unmet need in ophthalmic device reprocessing-offering a fast, safe and practical alternative to the outdated and often hazardous methods still in use.공시 • Apr 11Tristel plc Submits Additional Information to the FDA for Tristel OPHTristel plc confirmed it has submitted the additional information requested by the U.S. Food and Drug Administration (FDA) for Tristel OPH, a high-level disinfectant foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters and lenses that make contact with the cornea. The Company now expects a decision from the FDA by the end of June 2025. As announced in September 2024, the 510(k) filing for Tristel OPH will use Tristel ULT as its predicate device. Tristel ULT, a high-level disinfectants labelled for use on endocavity ultrasound probes and skin surface transducers, was cleared for sale in the US by the FDA in June 2023, following the Company's De Novo submission. With c.16 million ultrasound procedures taking place every year in North America, the Board continues to believe that FDA clearance has the potential to transform ophthalmic disinfection practice in the region. Tristel OPH addresses operational inefficiencies arising from complex and time-consuming decontamination practice. In addition, very few semi-critical ophthalmic devices are subject to effective high-level disinfection in the US. Low-level disinfectant options such as alcohol wipes are used as an alternative, or devices may be wet in sodium hypochlorite (Milton) or hydrogen peroxide in open trays with long contacts times.공시 • Feb 24Tristel plc Recommends an Interim Dividend for the Year Ended 30 June 2025, Payable on 11 April 2025The Board of Tristel plc is recommending an interim dividend of 5.68 pence for the year ended 30 June 2025 (2023: 5.24 pence) to be paid on 11 April 2025. The associated ex-dividend date will be 20 March 2025 with a record date of 21 March 2025.공시 • Dec 16Tristel plc to Report First Half, 2025 Results on Feb 24, 2025Tristel plc announced that they will report first half, 2025 results on Feb 24, 2025공시 • Nov 23Tristel plc, Annual General Meeting, Dec 16, 2024Tristel plc, Annual General Meeting, Dec 16, 2024. Location: the companys headquarters, unit 1b lynx business park, fordham road, newmarket, cambridgeshire, cb8 7ny, snailwell United Kingdom공시 • Oct 21Tristel plc Recommends Final Dividend, Payable on 20 December 2024The Board of Tristel plc is recommending a final dividend of 8.28 pence (2023: 7.88 pence). Combined with the interim dividend of 5.24 pence, the total dividend pay-out for the year will be 13.52 pence per share, this is an increase of 29% on last year's total dividend pay-out of 10.50 pence. Going forward the Board's intention is to increase the dividend annually in line with the year's increase in EPS, committing to minimum dividend growth of 5%. This final dividend will be paid on 20 December 2024, to shareholders on the register on 29 November 2024, the associated ex-dividend date is 28 November 2024.공시 • Oct 01Tristel plc to Report Fiscal Year 2024 Results on Oct 21, 2024Tristel plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Oct 21, 2024공시 • Sep 12Tristel plc Announces Filing of Premarket Notification 510(K) with the US Food and Drug Administration for Tristel OPHTristel plc announced that it has filed a Premarket Notification 510(k) with the US Food and Drug Administration ("FDA") for Tristel OPH, a high-level disinfectant ("HLD") foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters and lenses that make contact with the cornea. The 510(k) filing for Tristel OPH will use Tristel ULT as its predicate device. Tristel ULT, a HLD labelled for use onendocavity ultrasound probes and skin surface transducers, was cleared for sale in the US by the FDA in June 2023, following the Company's De Novo submission. The Board believes that FDA clearance has the potential to transform ophthalmic disinfection practice in North America. According to the Spaulding classification1, semi-critical devices require reprocessing with a HLD because they touch mucous membranes or non-intact skin, which is the case for nearly all ophthalmic devices. Very few semi-critical ophthalmic devices are subjected to an effective HLD in the US. Low-level disinfectant options such as alcohol wipes are used as an alternative, or devices may be soaked in sodium hypochlorite (bleach) or hydrogen peroxide in open trays with long contacts times.공시 • Sep 02Tristel plc Announces Bart Leemans Will Step Down from Position of Executive DirectorTristel plc announced that Bart Leemans will step down from the Tristel Board as an Executive Director. He will remain with the business and continue to focus his efforts on the French market in his capacity as Managing Director, Tristel SAS. There are no current plans to replace Bart on the Tristel Board. Bart was appointed in November 2018 following Tristel's acquisition of his business, the Ecomed Group, the Company's then distributor in Belgium, the Netherlands and France.공시 • May 09Tristel plc Announces the Publication of A White Paper Simplifying High-Level Disinfection for Urological ProceduresTristel plc welcomes the publication of a white paper ‘ Simplifying High-Level Disinfection for Urological Procedures: A Case Study’ at the American Urological Association (‘AUA’) 2024 conference, the gathering of urologists in the world. In June 2023 the Food and Drug Administration (‘FDA’) created a new category of Class II medical device disinfectants titled ‘foam or gel chemical sterilant/high-level disinfectant’ under which De Novo clearance for Tristeltm ULT was granted. As referenced within Dr. Allaway's study, Tristeltm ULT is recognised as a high level disinfectant (‘HLD’) and is effective against pathogens ranging from Human papillomavirus (‘HPV’) type 16 and type 18 to Mycobacterium terrae. Tristeltm ULT helps to address numerous bottlenecks that can impact workflow in a busy urology practice. One of the most time-consuming tasks is reprocessing medical devices between procedures. Chemical soaking and misting methods of HLD can damage probes and require complex workflows limiting the number of procedures clinicians can perform during a typical patient list.공시 • Jan 23Tristel plc Announces Canadian Regulatory Approval for Tristel Ult as a high-level disinfectantTristel plc announced that Health Canada has approved Tristel ULT as a Class II Medical Device for endocavity ultrasound probes and skin surface transducers. The timing of this regulatory approval comes well ahead of the Company's original aim for gaining approval before the end of H1 Fiscal Year 2025 and allows commercial launch during fiscal 2024. Health Canada approval, alongside approval from the US Food and Drug Administration received in June 2023, means that Tristel ULT can now be manufactured and sold throughout the whole of North America by Tristel's commercial partner Parker Laboratories Inc. as a high-level disinfectant for ultrasound instruments. Parker completed its first production run of Tristel ULT in October 2023 and is actively introducing the product to its United States distribution network. This activity will now be extended to the Canadian market. The first hospital users in the United States are trialling and purchasing the product. Tristel will provide a more detailed update in its interim results on 26 February 2024. Tristel is preparing its dossier for Tristel OPH, a high-level disinfectant For use on ophthalmic instruments, for submission to the FDA and has requested a pre-submission meeting with the agency. The review meeting date is scheduled for early March 2024. The Company anticipates completing its submission seeking 510(k) approval in the summer and receiving FDA approval by the end of the year. Tristel OPH was approved by Health Canada in June 2021. Tristel OPH were launched into the Canadian ophthalmic market as a high-level disinfectants for ophthalmic instruments including re-usable tonometers and lenses that contact the cornea during the Company's last financial year. The product is being distributed throughout the country by Innova Medical Ophthalmics Inc., Toronto, a subsidiary of Advancing Eyecare, Jacksonville, Florida. Tristel OPH is being used by public health authorities in all the major Canadian provinces.공시 • Dec 19+ 2 more updatesPaul Swinney Intends to Retire as Group CEO of Tristel plcTristel plc announced that Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates. The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.공시 • Oct 16+ 1 more updateTristel plc, Annual General Meeting, Dec 19, 2023Tristel plc, Annual General Meeting, Dec 19, 2023.공시 • Sep 12Tristel plc to Report Fiscal Year 2023 Results on Oct 16, 2023Tristel plc announced that they will report fiscal year 2023 results on Oct 16, 2023공시 • Sep 05Tristel plc Announces Regulatory Approval for EPA, Canada and South KoreaTristel plc announced that it has received three significant regulatory approvals. United States Environmental Protection Agency (EPA) Tristel received its first approval from the EPA for its foam-based disinfectant for surfaces in April 2018. The company successfully enhanced the performance claims of the product with a second approval in January 2019 and then registered the product in three States before curtailing the nationwide registration programme until a third submission could be made to bolster further the competitive positioning of the product. This submission was made in October 2020 and the company have now received the third approval for Jet. This expands the product's efficacy claims to include mycobacteria, and all efficacy claims are within a contact time of two minutes. The company expects to complete State-by-State registration by the end of June 2022, including California where company existing registration will require amendment, which can be a lengthy process.이익 및 매출 성장 예측OTCPK:TSNL.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/20286211121546/30/2027569101466/30/2026518912512/31/2025508910N/A9/30/2025487910N/A6/30/2025467810N/A3/31/2025456810N/A12/31/2024446811N/A9/30/2024436811N/A6/30/2024426911N/A3/31/2024416811N/A12/31/2023396810N/A9/30/202338579N/A6/30/202336468N/A3/31/202335467N/A12/31/202233356N/A9/30/202232256N/A6/30/202231156N/A3/31/202232046N/A12/31/202131156N/A9/30/202131256N/A6/30/202131457N/A3/31/202131457N/A12/31/202032557N/A9/30/202032557N/A6/30/202032557N/A3/31/202030557N/A12/31/201929557N/A9/30/2019274N/A6N/A6/30/2019264N/A5N/A3/31/2019254N/A6N/A12/31/2018243N/A6N/A9/30/2018233N/A5N/A6/30/2018223N/A4N/A3/31/2018223N/A4N/A12/31/2017214N/A4N/A9/30/2017213N/A4N/A6/30/2017203N/A4N/A3/31/2017203N/A4N/A12/31/2016193N/A4N/A9/30/2016183N/A4N/A6/30/2016172N/A5N/A3/31/2016172N/A4N/A12/31/2015162N/A4N/A9/30/2015162N/A3N/A6/30/2015152N/A3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TSNL.F 의 연간 예상 수익 증가율(14.6%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: TSNL.F 의 연간 수익(14.6%)이 US 시장(17.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: TSNL.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: TSNL.F 의 수익(연간 10%)이 US 시장(연간 12.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: TSNL.F 의 수익(연간 10%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TSNL.F의 자본 수익률은 3년 후 27.3%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 05:44종가2026/05/05 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tristel plc는 5명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christopher DonnellanCavendishKane SlutzkinDeutsche BankJens LindqvistInvestec Bank plc (UK)2명의 분석가 더 보기
공시 • Mar 03Tristel plc Recommends Interim Dividend for the Year Ended 30 June 2026, Payable on 9 April 2026The Board of Tristel plc recommended an interim dividend of 5.68 pence (2024: 5.68 pence) for the year ended 30 June 2026 to be paid on 9 April 2026. The associated ex-dividend date will be 19 March 2026 with a record date of 20 March 2026.
공시 • Feb 06Tristel plc to Report First Half, 2026 Results on Mar 02, 2026Tristel plc announced that they will report first half, 2026 results on Mar 02, 2026
공시 • Jan 22Tristel plc Announces Resignation of Matt Sassone as Chief Executive OfficerTristel plc announced that Matt Sassone, Chief Executive Officer, has confirmed to the Board his decision to resign to take up a worldwide President role with a large US multinational, leading a significant global business. Matt will actively continue in post until the end of the financial year and has fully committed to continue leading the business through this period. The Board has already commenced the process to appoint a new CEO and is confident that there is sufficient management depth in the business to ensure that trading will not be impacted during the transition.
공시 • Nov 24Tristel plc Updates US Guidelines for High Level DisinfectionTristel plc expanded guidelines on the handling and reprocessing of ultrasound probes in healthcare environments. For the first time, the AIUM guidelines include chlorine dioxide as an accepted option for high-level disinfection ("HLD"). Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is manufactured and distributed by Parker Laboratories under an exclusive partnership agreement with Tristel, and is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes available in the US market.
공시 • Nov 18Tristel plc, Annual General Meeting, Dec 11, 2025Tristel plc, Annual General Meeting, Dec 11, 2025. Location: the companys registered office, unit 1b lynx business park, fordham road snailwell, newmarket, cambridgeshire, cb8 7ny, United Kingdom
공시 • Sep 27Tristel plc Announces the Launch of Its New Ultrasound Probe Decontamination ProductTristel plc announced the launch of its new ultrasound probe decontamination product, Tristel VISICLEAN™?, the first detergent of its kind with colour technology, enabling visible coverage and confirmation of high level disinfection. Tristel VISICLEANtm is deployed on the ultrasound probe, dying it pink, and when exposed to Tristel ClO2 via Tristel DUO ULT™?, the pink dye disappears, visibly verifying that the probe has been high level disinfected. Tristel VISICLE AN™? is now available within the VISI Combination Pack, a convenient, all-in-one solution for ultrasound probe decontamination. Effective high-level disinfection begins with cleaning, which eliminates organic matter and reduces microbes to ensure proper sterilisation. This is performed manually and must be done each time. Tristel VISICLEan™? is the only cleaning solution with visible verification, ensuring full auditability and compliance with protocols. Tristel VISICLEAC™?, DUO ULT™? and DRY WIPEStm, the products within the VISI Combination pack includes the Company's new product, Tristel VISVEAN™?, along with two pre-existing products, Tristel DUO U LT™? & Tristel DRY WIPESt m. Together, these products enable clinicians to perform manual decontamination procedures with confidence, precision, and audit-ready traceability via Tristel's 3T™? digital platform. VISI Combination Packs are now available to healthcare providers across the UK and are being launched globally on a phased basis, as and when the Company secures the necessary local regulatory clearances. Tristel's proprietary chlorine dioxide chemistry is globally trusted for its broad-spectrum efficacy and resistance-proof mechanism. With over 30 years of experience in high-level disinfection, Tristel continues to remain at the forefront of infection prevention.
공시 • Sep 16Tristel plc to Report Fiscal Year 2025 Results on Oct 13, 2025Tristel plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Oct 13, 2025
공시 • May 12Tristel plc Announces FDA Clearance for Tristel OPH Ophthalmic High-Level Disinfectant Now Approved for Immediate Sale in the USTristel plc announced that the U S Food and Drug Administration ("FDA") has completed its review of the Company's 510(k) filing for Tristel OPH, and has granted its clearance for immediate sale. Tristel OPH is a high-level disinfectant ("HLD") foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters, lenses, retinal imaging probes, A-scan and B-scan biometry probes that make contact with the cornea. With c.16 million ophthalmic procedures taking place every year in North America, the Board believes that FDA clearance has the potential to transform ophthalmic disinfection practice in the region. Until now, the only FDA-cleared HLD method available for ophthalmic devices involves soaking in an open tray. This method is slow, given the long contact times required to be effective, and has as a result proven to be impractical to implement at point of care. In addition, the use of chemicals, such as sodium hypochlorite or hydrogen peroxide in an open tray, leads to occupational health concerns and may require costly implementation of ventilation. Prolonged exposure in a chemical soak can also lead to device damage. To address the problems, some clinics have turned to costly single-use devices, for which there is not always an option, while others have compromised by using low-level disinfectants options, such as alcohol wipes. In comparison, Tristel OPH has a short contact time of two minutes, is compatible with all widely used ophthalmic medical devices, is easily used at the point of care and is instantly deployable. The Company has already established local US manufacturing with its partner Parker Laboratories, and numerous leading eye institutes in the US have already approached Tristel to become early adopters in anticipation of FDA clearance for Tristel OPH. Tristel OPH directly addresses a long-standing unmet need in ophthalmic device reprocessing-offering a fast, safe and practical alternative to the outdated and often hazardous methods still in use.
공시 • Apr 11Tristel plc Submits Additional Information to the FDA for Tristel OPHTristel plc confirmed it has submitted the additional information requested by the U.S. Food and Drug Administration (FDA) for Tristel OPH, a high-level disinfectant foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters and lenses that make contact with the cornea. The Company now expects a decision from the FDA by the end of June 2025. As announced in September 2024, the 510(k) filing for Tristel OPH will use Tristel ULT as its predicate device. Tristel ULT, a high-level disinfectants labelled for use on endocavity ultrasound probes and skin surface transducers, was cleared for sale in the US by the FDA in June 2023, following the Company's De Novo submission. With c.16 million ultrasound procedures taking place every year in North America, the Board continues to believe that FDA clearance has the potential to transform ophthalmic disinfection practice in the region. Tristel OPH addresses operational inefficiencies arising from complex and time-consuming decontamination practice. In addition, very few semi-critical ophthalmic devices are subject to effective high-level disinfection in the US. Low-level disinfectant options such as alcohol wipes are used as an alternative, or devices may be wet in sodium hypochlorite (Milton) or hydrogen peroxide in open trays with long contacts times.
공시 • Feb 24Tristel plc Recommends an Interim Dividend for the Year Ended 30 June 2025, Payable on 11 April 2025The Board of Tristel plc is recommending an interim dividend of 5.68 pence for the year ended 30 June 2025 (2023: 5.24 pence) to be paid on 11 April 2025. The associated ex-dividend date will be 20 March 2025 with a record date of 21 March 2025.
공시 • Dec 16Tristel plc to Report First Half, 2025 Results on Feb 24, 2025Tristel plc announced that they will report first half, 2025 results on Feb 24, 2025
공시 • Nov 23Tristel plc, Annual General Meeting, Dec 16, 2024Tristel plc, Annual General Meeting, Dec 16, 2024. Location: the companys headquarters, unit 1b lynx business park, fordham road, newmarket, cambridgeshire, cb8 7ny, snailwell United Kingdom
공시 • Oct 21Tristel plc Recommends Final Dividend, Payable on 20 December 2024The Board of Tristel plc is recommending a final dividend of 8.28 pence (2023: 7.88 pence). Combined with the interim dividend of 5.24 pence, the total dividend pay-out for the year will be 13.52 pence per share, this is an increase of 29% on last year's total dividend pay-out of 10.50 pence. Going forward the Board's intention is to increase the dividend annually in line with the year's increase in EPS, committing to minimum dividend growth of 5%. This final dividend will be paid on 20 December 2024, to shareholders on the register on 29 November 2024, the associated ex-dividend date is 28 November 2024.
공시 • Oct 01Tristel plc to Report Fiscal Year 2024 Results on Oct 21, 2024Tristel plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Oct 21, 2024
공시 • Sep 12Tristel plc Announces Filing of Premarket Notification 510(K) with the US Food and Drug Administration for Tristel OPHTristel plc announced that it has filed a Premarket Notification 510(k) with the US Food and Drug Administration ("FDA") for Tristel OPH, a high-level disinfectant ("HLD") foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters and lenses that make contact with the cornea. The 510(k) filing for Tristel OPH will use Tristel ULT as its predicate device. Tristel ULT, a HLD labelled for use onendocavity ultrasound probes and skin surface transducers, was cleared for sale in the US by the FDA in June 2023, following the Company's De Novo submission. The Board believes that FDA clearance has the potential to transform ophthalmic disinfection practice in North America. According to the Spaulding classification1, semi-critical devices require reprocessing with a HLD because they touch mucous membranes or non-intact skin, which is the case for nearly all ophthalmic devices. Very few semi-critical ophthalmic devices are subjected to an effective HLD in the US. Low-level disinfectant options such as alcohol wipes are used as an alternative, or devices may be soaked in sodium hypochlorite (bleach) or hydrogen peroxide in open trays with long contacts times.
공시 • Sep 02Tristel plc Announces Bart Leemans Will Step Down from Position of Executive DirectorTristel plc announced that Bart Leemans will step down from the Tristel Board as an Executive Director. He will remain with the business and continue to focus his efforts on the French market in his capacity as Managing Director, Tristel SAS. There are no current plans to replace Bart on the Tristel Board. Bart was appointed in November 2018 following Tristel's acquisition of his business, the Ecomed Group, the Company's then distributor in Belgium, the Netherlands and France.
공시 • May 09Tristel plc Announces the Publication of A White Paper Simplifying High-Level Disinfection for Urological ProceduresTristel plc welcomes the publication of a white paper ‘ Simplifying High-Level Disinfection for Urological Procedures: A Case Study’ at the American Urological Association (‘AUA’) 2024 conference, the gathering of urologists in the world. In June 2023 the Food and Drug Administration (‘FDA’) created a new category of Class II medical device disinfectants titled ‘foam or gel chemical sterilant/high-level disinfectant’ under which De Novo clearance for Tristeltm ULT was granted. As referenced within Dr. Allaway's study, Tristeltm ULT is recognised as a high level disinfectant (‘HLD’) and is effective against pathogens ranging from Human papillomavirus (‘HPV’) type 16 and type 18 to Mycobacterium terrae. Tristeltm ULT helps to address numerous bottlenecks that can impact workflow in a busy urology practice. One of the most time-consuming tasks is reprocessing medical devices between procedures. Chemical soaking and misting methods of HLD can damage probes and require complex workflows limiting the number of procedures clinicians can perform during a typical patient list.
공시 • Jan 23Tristel plc Announces Canadian Regulatory Approval for Tristel Ult as a high-level disinfectantTristel plc announced that Health Canada has approved Tristel ULT as a Class II Medical Device for endocavity ultrasound probes and skin surface transducers. The timing of this regulatory approval comes well ahead of the Company's original aim for gaining approval before the end of H1 Fiscal Year 2025 and allows commercial launch during fiscal 2024. Health Canada approval, alongside approval from the US Food and Drug Administration received in June 2023, means that Tristel ULT can now be manufactured and sold throughout the whole of North America by Tristel's commercial partner Parker Laboratories Inc. as a high-level disinfectant for ultrasound instruments. Parker completed its first production run of Tristel ULT in October 2023 and is actively introducing the product to its United States distribution network. This activity will now be extended to the Canadian market. The first hospital users in the United States are trialling and purchasing the product. Tristel will provide a more detailed update in its interim results on 26 February 2024. Tristel is preparing its dossier for Tristel OPH, a high-level disinfectant For use on ophthalmic instruments, for submission to the FDA and has requested a pre-submission meeting with the agency. The review meeting date is scheduled for early March 2024. The Company anticipates completing its submission seeking 510(k) approval in the summer and receiving FDA approval by the end of the year. Tristel OPH was approved by Health Canada in June 2021. Tristel OPH were launched into the Canadian ophthalmic market as a high-level disinfectants for ophthalmic instruments including re-usable tonometers and lenses that contact the cornea during the Company's last financial year. The product is being distributed throughout the country by Innova Medical Ophthalmics Inc., Toronto, a subsidiary of Advancing Eyecare, Jacksonville, Florida. Tristel OPH is being used by public health authorities in all the major Canadian provinces.
공시 • Dec 19+ 2 more updatesPaul Swinney Intends to Retire as Group CEO of Tristel plcTristel plc announced that Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates. The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.
공시 • Oct 16+ 1 more updateTristel plc, Annual General Meeting, Dec 19, 2023Tristel plc, Annual General Meeting, Dec 19, 2023.
공시 • Sep 12Tristel plc to Report Fiscal Year 2023 Results on Oct 16, 2023Tristel plc announced that they will report fiscal year 2023 results on Oct 16, 2023
공시 • Sep 05Tristel plc Announces Regulatory Approval for EPA, Canada and South KoreaTristel plc announced that it has received three significant regulatory approvals. United States Environmental Protection Agency (EPA) Tristel received its first approval from the EPA for its foam-based disinfectant for surfaces in April 2018. The company successfully enhanced the performance claims of the product with a second approval in January 2019 and then registered the product in three States before curtailing the nationwide registration programme until a third submission could be made to bolster further the competitive positioning of the product. This submission was made in October 2020 and the company have now received the third approval for Jet. This expands the product's efficacy claims to include mycobacteria, and all efficacy claims are within a contact time of two minutes. The company expects to complete State-by-State registration by the end of June 2022, including California where company existing registration will require amendment, which can be a lengthy process.